ClinicalTrials.gg
Status unknownNCT00422331Updated Aug 14, 2007

Safety and Efficacy Study of Lithium in Bipolar Disorder

A Phase 3 interventional study of Lithium Carbonate Capsule in Bipolar Disorder and Mania, sponsored by JDS Pharmaceuticals. Status unknown at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-08-14.

Sponsored by JDS Pharmaceuticals · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2007), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing Lithium Carbonate in Bipolar Disorder — 1 open to participants now, 1 under way, none of them phase 3. Lithium Carbonate · Bipolar Disorder.

Planned enrollment
3rd of 10
206 · median 140
Started
2007
the only one that year
Phase 3
5 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
1 of 11
JDS Pharmaceuticals

Among the 11 studies testing Lithium Carbonate in Bipolar Disorder, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 5 in phase 3, and was the 5th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

1 of the 11 studies testing Lithium Carbonate in Bipolar Disorder is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Lithium Carbonate

Lithium Carbonate: first FDA approval 1970 (LITHONATE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Lithium Carbonate in Bipolar Disorder, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.

03

Conditions studied

  • Bipolar Disorder
  • Mania

Keywords

  • Bipolar I Disorder
  • Bipolar Disorder
  • Lithium
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Bipolar 1 Disorder;
  • Hospitalized or in the process of being hospitalized for a manic or mixed episode

Exclusion criteria

Exclusion Criteria:

  • History of rapid cycling;
  • History of or adverse reaction to lithium
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
206 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. change from baseline in YMRS score

Secondary outcomes

  1. change from baseline in CGI-BP score

  2. change from baseline in MADRS score

07

Study locations

1 site
  • JDS Pharmaceuticals
    New York, New York 10174, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2007
First posted
Jan 15, 2007
Start
Jan 2007
CompletionEst.
Dec 2007
Last update
Aug 14, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00422331
Lead sponsor
JDS Pharmaceuticals
First posted
Jan 15, 2007
Start date
Jan 2007
Completion
Dec 2007 (estimated)
Last update
Aug 14, 2007
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lithium Carbonate

Start the discussion